ATE417607T1 - Sphingolipide gegen krankhafte prozesse in lipid rafts - Google Patents
Sphingolipide gegen krankhafte prozesse in lipid raftsInfo
- Publication number
- ATE417607T1 ATE417607T1 AT05756574T AT05756574T ATE417607T1 AT E417607 T1 ATE417607 T1 AT E417607T1 AT 05756574 T AT05756574 T AT 05756574T AT 05756574 T AT05756574 T AT 05756574T AT E417607 T1 ATE417607 T1 AT E417607T1
- Authority
- AT
- Austria
- Prior art keywords
- sphingolipids
- lipid rafts
- against illegal
- illegal processes
- processes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04015248 | 2004-06-29 | ||
US63647104P | 2004-12-16 | 2004-12-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE417607T1 true ATE417607T1 (de) | 2009-01-15 |
Family
ID=35134634
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05756574T ATE417607T1 (de) | 2004-06-29 | 2005-06-29 | Sphingolipide gegen krankhafte prozesse in lipid rafts |
Country Status (9)
Country | Link |
---|---|
US (1) | US7629385B2 (de) |
EP (2) | EP2065040A3 (de) |
JP (1) | JP2008504330A (de) |
AT (1) | ATE417607T1 (de) |
AU (1) | AU2005259501A1 (de) |
CA (1) | CA2572310A1 (de) |
DE (1) | DE602005011802D1 (de) |
ES (1) | ES2317259T3 (de) |
WO (1) | WO2006002909A2 (de) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITRM20010688A1 (it) | 2001-11-21 | 2003-05-21 | Univ Roma | Composti immunoregolatori. |
EP1618876A1 (de) * | 2004-07-19 | 2006-01-25 | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO | Verwendung von Sphingolipiden zur Vorbeugung und Behandlung von Atherosklerose |
GB0513431D0 (en) * | 2005-06-30 | 2005-08-10 | Kherion Technology Ltd | Prophylactic compositions and uses |
WO2008111916A1 (en) * | 2007-03-09 | 2008-09-18 | Agency For Science, Technology And Research | Glycosphingolipid-aided intracellular delivery of cargo molecules |
DE102008002410A1 (de) * | 2008-06-13 | 2009-12-17 | Evonik Goldschmidt Gmbh | Enzymatische Synthese von Sphingolipiden |
DE102008002409A1 (de) | 2008-06-13 | 2009-12-17 | Evonik Goldschmidt Gmbh | Enzymatische Synthese von Sphingolipiden |
US8853452B2 (en) * | 2009-02-10 | 2014-10-07 | The Administrators Of The Tulane Educational Fund | Compounds, their syntheses, compositions, and methods to treat cancer |
US20120301457A1 (en) * | 2010-01-22 | 2012-11-29 | Surachai Supattapone | LIPID COFACTORS FOR FACILITATING PROPOGATION OF PRPsc |
US20130266977A1 (en) * | 2010-02-16 | 2013-10-10 | President And Fellows Of Harvard College | Methods and systems for detection of microbes |
WO2012012498A2 (en) | 2010-07-20 | 2012-01-26 | Pulmatrix, Inc. | Use of trp channel agonists to treat infections |
RU2017144619A (ru) | 2010-09-29 | 2019-02-20 | Пулмэтрикс, Инк. | Катионы одновалентных металлов сухих порошков для ингаляций |
ES2899621T3 (es) | 2010-09-29 | 2022-03-14 | Pulmatrix Operating Co Inc | Polvos secos catiónicos que comprenden sal de magnesio |
JP2013071918A (ja) * | 2011-09-28 | 2013-04-22 | Shiseido Co Ltd | フィラグリン産生促進剤 |
US20140336159A1 (en) | 2011-10-07 | 2014-11-13 | Pulmatrix, Inc. | Methods for treating and diagnosing respiratory tract infections |
WO2013130767A1 (en) | 2012-02-29 | 2013-09-06 | Pulmatrix, Inc. | Inhalable dry powders |
US20140316154A1 (en) | 2013-03-15 | 2014-10-23 | Cerenis Therapeutics Holding Sa | Methods for the synthesis of sphingomyelins and dihydrosphingomyelins |
US9708354B2 (en) | 2013-03-15 | 2017-07-18 | Cerenis Therapeutics Holding Sa | Methods for the synthesis of sphingomyelins and dihydrosphingomyelins |
JP6232008B2 (ja) * | 2015-03-19 | 2017-11-15 | 国立大学法人北海道大学 | 酸化抑制剤及びこれを用いた油脂含有飲食品 |
EP3259990A1 (de) * | 2016-06-20 | 2017-12-27 | Ceva Sante Animale | Verfahren zur bekämpfung von ektoparasiten bei nichtmenschlichen säugern |
DE102018217334A1 (de) * | 2018-10-10 | 2020-04-16 | Harbins Ruhr Bioscience, Inc. | Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel |
US11298412B2 (en) | 2020-07-16 | 2022-04-12 | Harbins Ruhr Bioscience, Inc. | Sphingoid compounds for prophylaxis and/or therapy of coronaviridae infection |
CN115894278A (zh) * | 2022-11-01 | 2023-04-04 | 深圳市迪克曼生物科技有限公司 | 亚麻酸衍生的神经酰胺及其制备方法和应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5411094A (en) * | 1992-11-12 | 1994-06-08 | Carnegie Institution Of Washington | Ceramide derivatives |
JPH08113535A (ja) * | 1994-10-13 | 1996-05-07 | Sumitomo Pharmaceut Co Ltd | 神経細胞の変性または死滅抑制剤 |
GB9614889D0 (en) * | 1996-07-16 | 1996-09-04 | John P Robarts Research Inst T | Ceramide promoters of haematopoiesis |
WO1999041266A1 (en) * | 1998-02-12 | 1999-08-19 | Emory University | Sphingolipid derivatives and their methods of use |
DE19841794A1 (de) | 1998-09-12 | 2000-03-16 | Beiersdorf Ag | Kombinationen von Antiadhäsiva (Ceramide und Sphingosine und Derivate) und Mikrobiziden |
US7820718B1 (en) | 1999-04-07 | 2010-10-26 | Roger Williams Hospital | Combinations of ceramide and chemotherapeutic agents for inducing cell death and uses thereof in treating cancer |
DE19946737A1 (de) | 1999-09-29 | 2001-04-19 | Max Planck Gesellschaft | Verwendung von Gangliosiden zur Modulation von Sphingolipid-Cholesterin-Mikrodomänen |
IL153331A0 (en) | 2000-06-14 | 2003-07-06 | Sankyo Co | A protein having ceramide kinase activity, dna encoding the same and methods for the preparation thereof |
WO2004006483A2 (en) | 2002-07-03 | 2004-01-15 | Endwave Corporation | N-way signal divider |
GB0301395D0 (en) * | 2003-01-21 | 2003-02-19 | Univ Aston | Inflammatory disorder treatment |
-
2005
- 2005-06-29 WO PCT/EP2005/007033 patent/WO2006002909A2/en active Application Filing
- 2005-06-29 US US11/571,354 patent/US7629385B2/en not_active Expired - Fee Related
- 2005-06-29 EP EP08021735A patent/EP2065040A3/de not_active Withdrawn
- 2005-06-29 DE DE602005011802T patent/DE602005011802D1/de active Active
- 2005-06-29 CA CA002572310A patent/CA2572310A1/en not_active Abandoned
- 2005-06-29 AT AT05756574T patent/ATE417607T1/de not_active IP Right Cessation
- 2005-06-29 AU AU2005259501A patent/AU2005259501A1/en not_active Abandoned
- 2005-06-29 ES ES05756574T patent/ES2317259T3/es active Active
- 2005-06-29 EP EP05756574A patent/EP1763342B1/de active Active
- 2005-06-29 JP JP2007518535A patent/JP2008504330A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2006002909A3 (en) | 2007-03-22 |
US20080090913A1 (en) | 2008-04-17 |
US7629385B2 (en) | 2009-12-08 |
AU2005259501A1 (en) | 2006-01-12 |
CA2572310A1 (en) | 2006-01-12 |
JP2008504330A (ja) | 2008-02-14 |
EP1763342B1 (de) | 2008-12-17 |
ES2317259T3 (es) | 2009-04-16 |
EP2065040A2 (de) | 2009-06-03 |
WO2006002909A2 (en) | 2006-01-12 |
EP2065040A3 (de) | 2009-09-09 |
EP1763342A2 (de) | 2007-03-21 |
DE602005011802D1 (de) | 2009-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE417607T1 (de) | Sphingolipide gegen krankhafte prozesse in lipid rafts | |
WO2007100366A3 (en) | Quinolone m1 receptor positive allosteric modulators | |
EP2305640A3 (de) | Substituierte Diphenyl-Ether, -Amine, -Sulfide und -Methane zur Behandlung von Beschwerden der Atemwege | |
NO20082768L (no) | Levodopa prodroge mesylat, sammensetninger og anvendelser derav | |
UA99309C2 (ru) | Замещенные пиперидинодигидротиенопиримидины | |
WO2008005534A3 (en) | Orally dissolving formulations of memantine | |
WO2007127505A3 (en) | Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system | |
UA84048C2 (ru) | Производные сульфонамида для лечения заболеваний, способ их получения (варианты), фармацевтическая композиция на их основе | |
WO2007075598A3 (en) | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | |
BRPI0516483A (pt) | preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade | |
BRPI0607017B8 (pt) | composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc | |
WO2006099941A8 (de) | Aminocarbonyl substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
CY1117326T1 (el) | Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson | |
CL2003002683A1 (es) | Enantiomeros s de compuestos derivados del acido (2s)-3-4(-{2-amino-2-oxoetoxi}fenil)-2-etoxipropanoico; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos de lipidos, | |
ECSP067043A (es) | Derivados de pirrolotriazina útiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogénesis | |
CL2007001882A1 (es) | Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos. | |
MX2013007319A (es) | Compuestos y su uso como inhibidores de sitio beta de escision de enzima (bace). | |
WO2007095050A3 (en) | N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase | |
DOP2007000053A (es) | Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo | |
NO20082124L (no) | Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom | |
CL2007001881A1 (es) | Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos. | |
CL2008000981A1 (es) | Compuestos derivados de imidazolidin-carboxamida; composicion farmaceutica; procedimiento de produccion de la composicion farmaceutica; y uso en el tratamiento y/o prevencion de trastornos ateroscleroticos, de metabolismo de acidos grasos y en los qu | |
BRPI0407662B8 (pt) | derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas | |
WO2007064932A3 (en) | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase | |
WO2006078576A3 (en) | Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |